Contrasting Haemonetics (HAE) and Alliqua Biomedical (ALQA)

Share on StockTwits

Haemonetics (NYSE: HAE) and Alliqua Biomedical (NASDAQ:ALQA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Insider and Institutional Ownership

99.3% of Haemonetics shares are owned by institutional investors. Comparatively, 16.5% of Alliqua Biomedical shares are owned by institutional investors. 1.0% of Haemonetics shares are owned by insiders. Comparatively, 13.2% of Alliqua Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Haemonetics and Alliqua Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Haemonetics 5.04% 12.71% 7.89%
Alliqua Biomedical -114.41% -122.50% -63.67%

Valuation & Earnings

This table compares Haemonetics and Alliqua Biomedical’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Haemonetics $903.92 million 5.37 $45.57 million $1.87 49.75
Alliqua Biomedical $19.57 million 0.51 -$25.70 million ($6.49) -0.31

Haemonetics has higher revenue and earnings than Alliqua Biomedical. Alliqua Biomedical is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Haemonetics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Alliqua Biomedical has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Haemonetics and Alliqua Biomedical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics 0 2 4 0 2.67
Alliqua Biomedical 0 1 0 0 2.00

Haemonetics presently has a consensus target price of $84.40, indicating a potential downside of 9.29%. Alliqua Biomedical has a consensus target price of $2.80, indicating a potential upside of 39.30%. Given Alliqua Biomedical’s higher probable upside, analysts clearly believe Alliqua Biomedical is more favorable than Haemonetics.

Summary

Haemonetics beats Alliqua Biomedical on 11 of the 14 factors compared between the two stocks.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies. It also provides contract manufacturing services, including the development, manufacture, and marketing of high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Yardley, Pennsylvania.

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply